Your session is about to expire
← Back to Search
T Cell Therapy for Leukemia
Study Summary
This trial will study whether adding regulatory T cells to a T cell-depleted graft can reduce the incidence of acute graft vs. host disease while augmenting the graft vs. leukemia effect and improving immune reconstitution in patients with hematologic malignancies undergoing allogeneic myeloablative HCT.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- Group 1: Dose escalation
Frequently Asked Questions
Is the age limit for enrollment in this study above 25 years?
"This investigation is open to participants aged 13 and up, but below the age of 60."
Are new participants currently being sought for this trial?
"Data on clinicaltrials.gov reveals that this medical research is not currently seeking participants, despite having been initially posted in December 2011 and most recently updated in May 2022. However, there are 3241 other trials actively recruiting presently."
What are the requirements for participation in this research project?
"This medical trial is enrolling 68 patients aged 13 to 60 years, who have diffuse lymphoma. Participants must also fulfil the following conditions: Monosomal karyotype (-5, 5q-, -7, 7q-), Recipient Inclusion Criteria, translocation of chromosomes 11 and 23 (t[11; q23]), t(9;11), inv(3), t(3;3) t(6;9) t(9;22), Normal karyotype with fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication mutation, Other high risk features as determined"
Share this study with friends
Copy Link
Messenger